Bristol-Myers Squibb to Cut Workforce by 10%
Bristol-Myers Squibb (BMS, New York, NY) has announced plans to reduce its workforce by approximately 4,800 positions, more than 10% of its current workforce.
Bristol-Myers Squibb (BMS, New York, NY) has announced plans to reduce its workforce by approximately 4,800 positions, more than 10% of its current workforce. The announcement of this restructuring comes as BMS tries to focus on pharmaceuticals rather than big-market drugs.
The locations for the layoffs have not been disclosed, but 1,300 employees have already been notified. Many of the positions are in human resources, information technology, and finance. An additional 3,500 jobs are expected to be cut by the end of next year.
BMS has also announced the closure of its Colón, Panama manufacturing plant, which will cease operations by the middle of 2008. According to the press release, the decision to close is a result of the decreased market demand for the products packaged at the site. The plant closing will affect 98 jobs.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
